Orally active aminopyridines as inhibitors of tetrameric fructose-1,6-bisphosphatase
摘要:
A novel sulfonylureido pyridine series exemplified by compound 19 yielded potent inhibitors of FBPase showing significant glucose reduction and modest glycogen lowering in the acute db/db mouse model for Type-2 diabetes. Our inhibitors occupy the allosteric binding site and also extend into the dyad interface region of tetrameric FBPase. (C) 2011 Elsevier Ltd. All rights reserved.
Pyridines as FBPase inhibitors for treatment of diabetes
申请人:Hoffmann-LA Roche Inc.
公开号:US08163778B2
公开(公告)日:2012-04-24
Compounds of formula (I)
as well as pharmaceutically acceptable salts and esters thereof wherein the residues have the significance given in claim 1 and which can be used in the form of pharmaceutical compositions.
[EN] PYRIDINE COMPOUNDS<br/>[FR] COMPOSÉS DE PYRIDINE
申请人:HOFFMANN LA ROCHE
公开号:WO2009068468A2
公开(公告)日:2009-06-04
Compounds of formula (I) as well as pharmaceutically acceptable salts and esters thereof wherein the residues have the significance given in claim 1 and which can be used in the form of pharmaceutical compositions.
Orally active aminopyridines as inhibitors of tetrameric fructose-1,6-bisphosphatase
作者:Paul Hebeisen、Wolfgang Haap、Bernd Kuhn、Peter Mohr、Hans Peter Wessel、Ulrich Zutter、Stephan Kirchner、Armin Ruf、Jörg Benz、Catherine Joseph、Rubén Alvarez-Sánchez、Marcel Gubler、Brigitte Schott、Agnes Benardeau、Effie Tozzo、Eric Kitas
DOI:10.1016/j.bmcl.2011.04.044
日期:2011.6
A novel sulfonylureido pyridine series exemplified by compound 19 yielded potent inhibitors of FBPase showing significant glucose reduction and modest glycogen lowering in the acute db/db mouse model for Type-2 diabetes. Our inhibitors occupy the allosteric binding site and also extend into the dyad interface region of tetrameric FBPase. (C) 2011 Elsevier Ltd. All rights reserved.